Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. filed an 8‑K on June 12, 2026 disclosing a Purchase Agreement dated June 10, 2026 with FireFish TopCo, LLC to buy all equity interests in certain subsidiaries and the assets of other business entities that together operate an automotive driver‑control systems business. The base Purchase Price is $30,000,000 plus an $800,000 deferred‑revenue credit, with the final “Closing Purchase Price” adjusted for income tax items and indebtedness of the transferred entities. The company also furnished a press release on June 12, 2026.

Key Details

• Purchase Price: $30,000,000 + $800,000 deferred‑revenue credit, less income tax obligations (net) and indebtedness at closing.
• Closing condition: Seller must deliver PCAOB audits for fiscal years 2024 and 2025 with an unqualified opinion and Gross Profit minus capital expenditures of at least $12,000,000 for those years; if that condition is not met by the Outside Date of September 10, 2026, Aspire may terminate.
• Termination fee: If terminated under certain specified circumstances, the non‑terminating party may owe a one‑time $3,500,000 liquidated damages payment.
• Scope: Transaction covers equity in specified Transferred Entities and substantially all assets of the U.S. Enterprise and KOP Enterprise (driver control systems business units, including operations in Kopřivnice, Czech Republic).

Why It Matters
This 8‑K discloses a material acquisition that would add an automotive driver‑control systems business to Aspire’s holdings for a defined cash price subject to customary adjustments and closing conditions. Investors should note the dependency on clean PCAOB audits and the $12M gross‑profit‑minus‑capex threshold — failure to meet those requirements by Sept. 10, 2026 gives Aspire a clear exit right. The agreement also includes a significant termination fee and customary indemnities, which are relevant to deal risk and potential cash obligations.